{"page_content": "Healthy People\n21  |  ENVIRONMENTAL, SOCIAL & GOVERNANCE REPORT 2021\nIntroduction COVID-19 Response Healthy Society Healthy Planet A Healthy Amgen Appendix\nHEAL TH EQUITY SUMMIT \nFIVE KEY TAKEAWAYS\nTECHNOLOGY IS A TOOL  \nand a challenge in addressing \nhealth disparities  .\nPATIENT-CENTRIC,  \nCUL TURALL Y SENSITIVE  \napproach to care is critical .COMMUNITY-BASED \nservices form a foundation to \naddress health inequities  . SOCIAL CARE & DIGNITY \nsit at the heart of health equity  .COVID-19 has brought \nyears-old health equity issues \nto the forefront .Raising the Spotlight on Health Inequities \nIn 2021, we partnered with a national health equity advisory \ngroup of state legislators from 16 U .S .  states and four \nnational caucuses of color\u2014the National Black Caucus of \nState Legislators, the National Hispanic Caucus of State \nLegislators, the National Asian Pacific American Caucus of \nState Legislators, and the National Caucus of Native American \nState Legislators\u2014to support bipartisan dialogue on health \nequity  . Through a series of town hall discussions and \neducational resources, we are working to support policy \nchange that will address barriers to care facing historically \nunderrepresented communities  . \n\u201cTogether we can work toward a country where your \nbackground, your ZIP code and your income do not \ndetermine whether you have access to quality affordable \ncare,\u201d said Congressman Raul Ruiz, MD, U .S .  Representative \nfor California\u2019s 36th Congressional District and Chair of the \nCongressional Hispanic Caucus, at the 2021 Amgen Health \nEquity Summit .\nAt our 8th Annual Health Equity Summit we focused on \ndisrupting health disparities through partnership  . The virtual \nevent included more than 500 participants from seven \ncountries representing patient advocacy organizations, \nphysician associations, medical institutions, academia, and \nthe private sector  . Discussions from the summit yielded \nfive key takeaways  . HEAL TH EQUITYWorking to Increase Diversity and Improve \nRepresentation in Clinical Trials \nThe underrepresentation of racial and ethnic minority \npatients in clinical trials contributes to the collection of \nincomplete or limited trial data, limited access to innovative \ntreatment for vulnerable populations, and disparities in \nhealth outcomes  . Barriers to participation include mistrust, \nlack of awareness, logistical challenges such as transportation, \nand provider bias  . \nRacial and ethnic minority groups have been underrepresented \nin clinical trials vs  . the proportion of the general population \nthat they represent .\n\u2022  Black Americans bear a disproportionate share of the cancer \nburden, having the highest death rate and the lowest survival \nrate of any racial or ethnic group in the U .S .  for most cancers  . \nYet according to the U .S .  Food and Drug Administration \n(FDA), in 2019 alone, of the participants in oncology trials, \n73% were White, 18% were Asian, 4% were Black American \nand 5% were Hispanic  .\n\u2022  Black Americans are 30% more likely to die from heart  \ndisease than non-Hispanic Whites, but they make up only \n2 .5% of cardiovascular disease clinical trials  .\n\u2022  Black and Hispanic Americans patients suffer  \ndisproportionately from severe asthma .  However,  \nthey are often underrepresented within clinical trials  \nof asthma therapies  .\nAmgen is working to improve the proportional representation \nof trial participants in clinical trials by addressing key systemic \nissues that deter people from participating in research, ", "metadata": {"source": "NASDAQ_AMGN_2021.pdf", "page": 20, "parser": "pypdf", "split_method": "page", "run_time": "2024-05-29 08:35:04"}, "type": "Document"}